Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia
- PMID: 21481785
- DOI: 10.1016/j.ccr.2011.03.019
Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia
Abstract
ABL inhibitors have revolutionized the clinical management of chronic myeloid leukemia, but the BCR-ABL(T315I) mutation confers resistance to currently approved drugs. Chan et al. show, in this issue of Cancer Cell, that "switch-control" inhibitors block BCR-ABL(T315I) activity by preventing ABL from switching from the inactive to active conformation.
Copyright © 2011 Elsevier Inc. All rights reserved.
Comment on
-
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.Cancer Cell. 2011 Apr 12;19(4):556-68. doi: 10.1016/j.ccr.2011.03.003. Cancer Cell. 2011. PMID: 21481795 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
